|
1
|
Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, Zhang L, Fan G, Xu J, Gu X, et al: Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 395:497–506. 2020.PubMed/NCBI View Article : Google Scholar
|
|
2
|
World Health Organization (WHO): Novel Coronavirus (2019-nCoV). WHO, Geneva, 2020. https://www.who.int/emergencies/diseases/novel-coronavirus-2019. Accessed February 7, 2020.
|
|
3
|
World Health Organization (WHO): WHO Coronavirus (COVID-19) Dashboard. WHO, Geneva, 2021. https://covid19.who.int/. Accessed August 18, 2021.
|
|
4
|
Kuba K, Imai Y and Penninger JM: Multiple functions of angiotensin-converting enzyme 2 and its relevance in cardiovascular diseases. Circ J. 77:301–308. 2013.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Fukui K, Yang Q, Cao Y, Takahashi N, Hatakeyama H, Wang H, Wada J, Zhang Y, Marselli L, Nammo T, et al: The HNF-1 target Collectrin controls insulin exocytosis by SNARE complex formation. Cell Metab. 2:373–384. 2005.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Gallagher PE, Ferrario CM and Tallant EA: Regulation of ACE2 in cardiac myocytes and fibroblasts. Am J Physiol Heart Circ Physiol. 295:H2373–H2379. 2008.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Warner FJ, Lew RA, Smith AI, Lambert DW, Hooper NM and Turner AJ: Angiotensin-converting enzyme 2 (ACE2), but not ACE, is preferentially localized to the apical surface of polarized kidney cells. J Biol Chem. 280:39353–39362. 2005.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Tseng CT, Tseng J, Perrone L, Worthy M, Popov V and Peters CJ: Apical entry and release of severe acute respiratory syndrome-associated coronavirus in polarized Calu-3 lung epithelial cells. J Virol. 79:9470–9479. 2005.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Tai W, He L, Zhang X, Pu J, Voronin D, Jiang S, Zhou Y and Du L: Characterization of the receptor-binding domain (RBD) of 2019 novel coronavirus: Implication for development of RBD protein as a viral attachment inhibitor and vaccine. Cell Mol Immunol. 17:613–620. 2020.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Coutard B, Valle C, de Lamballerie X, Canard B, Seidah NG and Decroly E: The spike glycoprotein of the new coronavirus 2019-nCoV contains a furin-like cleavage site absent in CoV of the same clade. Antiviral Res. 176(104742)2020.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Daniloski Z, Jordan TX, Ilmain JK, Guo X, Bhabha G, tenOever BR and Sanjana NE: The Spike D614G mutation increases SARS-CoV-2 infection of multiple human cell types. Elife. 10(e65365)2021.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Ortega MA, Fraile-Martínez O, García-Montero C, García-Gallego S, Sánchez-Trujillo L, Torres-Carranza D, Álvarez-Mon MÁ, Pekarek L, García-Honduvilla N, Bujan J, et al: An integrative look at SARS-CoV-2 (Review). Int J Mol Med. 47:415–434. 2021.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Kim SR, Nam SH and Kim YR: Risk factors on the progression to clinical outcomes of COVID-19 patients in South Korea: Using national data. Int J Environ Res Public Health. 17(8847)2020.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Tian J, Yuan X, Xiao J, Zhong Q, Yang C, Liu B, Cai Y, Lu Z, Wang J, Wang Y, et al: Clinical characteristics and risk factors associated with COVID-19 disease severity in patients with cancer in Wuhan, China: A multicentre, retrospective, cohort study. Lancet Oncol. 21:893–903. 2020.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Luo Y, Mao L, Yuan X, Xue Y, Lin Q, Tang G, Song H, Wang F and Sun Z: Prediction model based on the combination of cytokines and lymphocyte subsets for prognosis of SARS-CoV-2 infection. J Clin Immunol. 40:960–969. 2020.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Gong J, Ou J, Qiu X, Jie Y, Chen Y, Yuan L, Cao J, Tan M, Xu W, Zheng F, et al: A tool for early prediction of severe coronavirus disease 2019 (COVID-19): A multicenter study using the risk Nomogram in Wuhan and Guangdong, China. Clin Infect Dis. 71:833–840. 2020.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Ponti G, Maccaferri M, Ruini C, Tomasi A and Ozben T: Biomarkers associated with COVID-19 disease progression. Crit Rev Clin Lab Sci. 57:389–399. 2020.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Hu C, Liu Z, Jiang Y, Shi O, Zhang X, Xu K, Suo C, Wang Q, Song Y, Yu K, et al: Early prediction of mortality risk among patients with severe COVID-19, using machine learning. Int J Epidemiol. 49:1918–29. 2020.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Wynants L, Van Calster B, Collins GS, Riley RD, Heinze G, Schuit E, Bonten MMJ, Dahly DL, Damen JAA, Debray TPA, et al: Prediction models for diagnosis and prognosis of covid-19 infection: Systematic review and critical appraisal. BMJ. 369(m1328)2020.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Meng Z, Wang M, Zhao Z, Zhou Y, Wu Y, Guo S, Li M, Zhou Y, Yang S, Li W and Ying B: Development and validation of a predictive model for severe COVID-19: A Case-Control Study in China. Front Med (Lausanne). 8(663145)2021.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Álvarez-Mon M, Ortega MA, Gasulla Ó, Fortuny-Profitós J, Mazaira-Font FA, Saurina P, Monserrat J, Plana MN, Troncoso D, Moreno JS, et al: A predictive model and risk factors for case fatality of COVID-19. J Pers Med. 11(36)2021.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Li Q, Zhang J, Ling Y, Li W, Zhang X, Lu H and Chen L: A simple algorithm helps early identification of SARS-CoV-2 infection patients with severe progression tendency. Infection. 48:577–584. 2020.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Dong Y, Zhou H, Li M, Zhang Z, Guo W, Yu T, Gui Y, Wang Q, Zhao L, Luo S, et al: A novel simple scoring model for predicting severity of patients with SARS-CoV-2 infection. Transbound Emerg Dis. 67:2823–2829. 2020.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Schwab P, DuMont Schütte A, Dietz B and Bauer S: Clinical predictive models for COVID-19: Systematic study. J Med Internet Res. 22(e21439)2020.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Ho JK, Jeevan-Raj B and Netter HJ: Hepatitis B Virus (HBV) subviral particles as protective vaccines and vaccine platforms. Viruses. 12(126)2020.PubMed/NCBI View Article : Google Scholar
|
|
26
|
D'Amelio E, Salemi S and D'Amelio R: Anti-Infectious human vaccination in historical perspective. Int Rev Immunol. 35:260–290. 2016.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Sanders B, Koldijk M and Schuitemaker H: Inactivated viral vaccines. In: Vaccine Analysis: Strategies, Principles, and Control. Nunnally BK, Turula VE and Sitrin RD (eds). Springer Berlin Heidelberg, Berlin, Heidelberg, pp45-80, 2015.
|
|
28
|
Donaldson B, Lateef Z, Walker GF, Young SL and Ward VK: Virus-like particle vaccines: Immunology and formulation for clinical translation. Expert Rev Vaccines. 17:833–849. 2018.PubMed/NCBI View Article : Google Scholar
|
|
29
|
World Health Organization (WHO): COVID-19 vaccine tracker and landscape. WHO, Geneva, 2021. https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines. Accessed September 24, 2021.
|
|
30
|
Lee WS, Wheatley AK, Kent SJ and DeKosky BJ: Antibody-dependent enhancement and SARS-CoV-2 vaccines and therapies. Nat Microbiol. 5:1185–1191. 2020.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Gao Q, Bao L, Mao H, Wang L, Xu K, Yang M, Li Y, Zhu L, Wang N, Lv Z, et al: Development of an inactivated vaccine candidate for SARS-CoV-2. Science. 369:77–81. 2020.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Zhang Y, Zeng G, Pan H, Li C, Hu Y, Chu K, Han W, Chen Z, Tang R, Yin W, et al: Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18-59 years: A randomised, double-blind, placebo-controlled, phase 1/2 clinical trial. Lancet Infect Dis. 21:181–192. 2021.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Reuters: New Brazil Data Shows Disappointing 50.4% Efficacy for China's CoronaVac Vaccine. Reuters, London, 2021. https://www.reuters.com/article/healthcoronavirus-brazil-coronavirus-idUSE5N2HA01G. Accessed February 3, 2021.
|
|
34
|
Tanriover MD, Doğanay HL, Akova M, Güner HR, Azap A, Akhan S, Köse Ş, Erdinç FŞ, Akalın EH, Tabak ÖF, et al: Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): Interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey. Lancet. 398:213–222. 2021.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Soeriaatmadja W: Indonesia grants emergency use approval to Sinovac's vaccine, local trials show 65% efficacy. The StraitsTime, 2021. https://www.straitstimes.com/asia/se-asia/indonesia-grants-emergency-use-approval-to-sinovac-vaccine-local-trials-show-65. Updated January 12, 2021.
|
|
36
|
Wang H, Zhang Y, Huang B, Deng W, Quan Y, Wang W, Xu W, Zhao Y, Li N, Zhang J, et al: Development of an inactivated vaccine candidate, BBIBP-CorV, with potent protection against SARS-CoV-2. Cell. 182:713–721.e9. 2020.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Xia S, Zhang Y, Wang Y, Wang H, Yang Y, Gao GF, Tan W, Wu G, Xu M, Lou Z, et al: Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: A randomised, double-blind, placebo-controlled, phase 1/2 trial. Lancet Infect Dis. 21:39–51. 2021.PubMed/NCBI View Article : Google Scholar
|
|
38
|
Ura T, Okuda K and Shimada M: Developments in viral Vector-Based vaccines. Vaccines (Basel). 2:624–641. 2014.PubMed/NCBI View Article : Google Scholar
|
|
39
|
Gsell PS, Camacho A, Kucharski AJ, Watson CH, Bagayoko A, Nadlaou SD, Dean NE, Diallo A, Diallo A, Honora DA, et al: Ring vaccination with rVSV-ZEBOV under expanded access in response to an outbreak of Ebola virus disease in Guinea, 2016: An operational and vaccine safety report. Lancet Infect Dis. 17:1276–1284. 2017.PubMed/NCBI View Article : Google Scholar
|
|
40
|
Thomas SJ and Yoon IK: A review of Dengvaxia®: Development to deployment. Hum Vaccin Immunother. 15:2295–2314. 2019.PubMed/NCBI View Article : Google Scholar
|
|
41
|
Pollard AJ, Launay O, Lelievre JD, Lacabaratz C, Grande S, Goldstein N, Robinson C, Gaddah A, Bockstal V, Wiedemann A, et al: Safety and immunogenicity of a two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in adults in Europe (EBOVAC2): A randomised, observer-blind, participant-blind, placebo-controlled, phase 2 trial. Lancet Infect Dis. 21:493–506. 2021.PubMed/NCBI View Article : Google Scholar
|
|
42
|
EU Clinical Trials Register: A phase I/II Study to Determine Efficacy Safety Immunogenicity of the Candidate Coronavirus Disease (COVID-19) Vaccine ChAdOx1 nCoV-19 in UK Healthy Adult Volunteers. European Medicines Agency, Amsterdam 2020. https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001072-15/GB. Accessed July 7, 2020.
|
|
43
|
Logunov DY, Dolzhikova IV, Shcheblyakov DV, Tukhvatulin AI, Zubkova OV, Dzharullaeva AS, Kovyrshina AV, Lubenets NL, Grousova DM, Erokhova AS, et al: Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: An interim analysis of a randomised controlled phase 3 trial in Russia. Lancet. 397:671–681. 2021.PubMed/NCBI View Article : Google Scholar
|
|
44
|
Mercado NB, Zahn R, Wegmann F, Loos C, Chandrashekar A, Yu J, Liu J, Peter L, McMahan K, Tostanoski LH, et al: Single-shot Ad26 vaccine protects against SARS-CoV-2 in rhesus macaques. Nature. 586:583–588. 2020.PubMed/NCBI View Article : Google Scholar
|
|
45
|
Zhu FC, Guan XH, Li YH, Huang JY, Jiang T, Hou LH, Li JX, Yang BF, Wang L, Wang WJ, et al: Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: A randomised, double-blind, placebo-controlled, phase 2 trial. Lancet. 396:479–488. 2020.PubMed/NCBI View Article : Google Scholar
|
|
46
|
Corbett KS, Edwards DK, Leist SR, Abiona OM, Boyoglu-Barnum S, Gillespie RA, Himansu S, Schäfer A, Ziwawo CT, DiPiazza AT, et al: SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness. Nature. 586:567–571. 2020.PubMed/NCBI View Article : Google Scholar
|
|
47
|
Walsh EE, Frenck RW Jr, Falsey AR, Kitchin N, Absalon J, Gurtman A, Lockhart S, Neuzil K, Mulligan MJ, Bailey R, et al: Safety and immunogenicity of two RNA-Based Covid-19 vaccine candidates. N Engl J Med. 383:2439–2450. 2020.PubMed/NCBI View Article : Google Scholar
|
|
48
|
Mulligan MJ, Lyke KE, Kitchin N, Absalon J, Gurtman A, Lockhart S, Neuzil K, Raabe V, Bailey R, Swanson KA, et al: Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults. Nature. 586:589–593. 2020.PubMed/NCBI View Article : Google Scholar
|
|
49
|
Motamedi H, Ari MM, Dashtbin S, Fathollahi M, Hossainpour H, Alvandi A, Moradi J and Abiri R: An update review of globally reported SARS-CoV-2 vaccines in preclinical and clinical stages. Int Immunopharmacol. 96(107763)2021.PubMed/NCBI View Article : Google Scholar
|
|
50
|
The Pirbright Institute: Studies at Pirbright Demonstrate Two Doses of Oxford University's COVID-19 Vaccine Boosts Immune Response In Pigs. The Pirbright Institute, Woking, 2020. https://www.pirbright.ac.uk/press-releases/2020/06/studies-pirbright-demonstrate-two-doses-oxford-university%E2%80%99s-covid-19-vaccine. Accessed July 10, 2020.
|
|
51
|
Folegatti PM, Ewer KJ, Aley PK, Angus B, Becker S, Belij-Rammerstorfer S, Bellamy D, Bibi S, Bittaye M, Clutterbuck EA, et al: Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: A preliminary report of a phase 1/2, single-blind, randomised controlled trial. Lancet. 396:467–478. 2020.PubMed/NCBI View Article : Google Scholar
|
|
52
|
South African Medical Research Council, South African Cochrane Centre: COVID-19 Vaccine (ChAdOx1 nCoV-19) trial in South African Adults with without HIV-Infection. South African Medical Research Council, South African Cochrane Centre, Tygerberg 2020. https://pactr.samrc.ac.za/TrialDisplay.aspx?TrialID=12166. Accessed July 7, 2020.
|
|
53
|
ISRCTN Registry: A Phase III Study to Investigate a Vaccine Against COVID-19. ISRCTN Registry, London, 2020. http://www.isrctn.com/ISRCTN89951424. Accessed August 20, 2020.
|
|
54
|
US National Library of Medicine (NIH): Phase III Double-blind, Placebo-controlled Study of AZD1222 for the Prevention of COVID-19 in Adults. ClinicalTrials.gov Identifier: NCT04516746. NIH, Bethesda, MD, 2020. https://www.clinicaltrials.gov/ct2/show/NCT04516746. Accessed August 20, 2020.
|
|
55
|
Voysey M, Clemens SAC, Madhi SA, Weckx LY, Folegatti PM, Aley PK, Angus B, Baillie VL, Barnabas SL, Bhorat QE, et al: Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: An interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet. 397:99–111. 2021.PubMed/NCBI View Article : Google Scholar
|
|
56
|
Wang P, Nair MS, Liu L, Iketani S, Luo Y, Guo Y, Wang M, Yu J, Zhang B, Kwong PD, et al: Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7. Nature. 593:130–135. 2021.PubMed/NCBI View Article : Google Scholar
|
|
57
|
Madhi SA, Baillie V, Cutland CL, Voysey M, Koen AL, Fairlie L, Padayachee SD, Dheda K, Barnabas SL, Bhorat QE, et al: Efficacy of the ChAdOx1 nCoV-19 Covid-19 vaccine against the B.1.351 variant. N Engl J Med. 384:1885–1898. 2021.PubMed/NCBI View Article : Google Scholar
|
|
58
|
Dejnirattisai W, Zhou D, Supasa P, Liu C, Mentzer AJ, Ginn HM, Zhao Y, Duyvesteyn HME, Tuekprakhon A, Nutalai R, et al: Antibody evasion by the P.1 strain of SARS-CoV-2. Cell. 184:2939–2954.e9. 2021.PubMed/NCBI View Article : Google Scholar
|
|
59
|
Public Health England: Public Health England vaccine effectiveness report March 2021. Public Health England, London, 2021. https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/989360/PHE_COVID-19_vaccine_effectiveness_report_March_2021_v2.pdf.
|
|
60
|
Shah ASV, Gribben C, Bishop J, Hanln P, Caldwell D, Wood R, Reid M, McMenamin J, Goldberg D, Stockton D, et al: Effect of vaccination on transmission of COVID-19: an observational study in healthcare workers and their households. medRxiv: doi: https://doi.org/10.1101/2021.03.11.21253275.
|
|
61
|
COVID-19 vaccine AstraZeneca analysis print. Report Run Date: 22-Mar-2021 Data Lock Date: 14-Mar-2021 19:00:03 All UK spontaneous reports received between 4/01/21 and 14/03/21 for COVID-19 vaccine Oxford University/AstraZeneca. https://it.scribd.com/document/503301908/COVID-19-AstraZeneca-Vaccine-Analysis-Print. Accessed March 22, 2021.
|
|
62
|
Greinacher A, Thiele T, Warkentin TE, Weisser K, Kyrle PA and Eichinger S: Thrombotic thrombocytopenia after ChAdOx1 nCov-19 vaccination. N Engl J Med. 384:2092–2101. 2021.PubMed/NCBI View Article : Google Scholar
|
|
63
|
Schultz NH, Sørvoll IH, Michelsen AE, Munthe LA, Lund-Johansen F, Ahlen MT, Wiedmann M, Aamodt AH, Skattør TH, Tjønnfjord GE and Holme PA: Thrombosis and thrombocytopenia after ChAdOx1 nCoV-19 vaccination. N Engl J Med. 384:2124–2130. 2021.PubMed/NCBI View Article : Google Scholar
|
|
64
|
Scully M, Singh D, Lown R, Poles A, Solomon T, Levi M, Goldblatt D, Kotoucek P, Thomas W and Lester W: Pathologic antibodies to platelet factor 4 after ChAdOx1 nCoV-19 vaccination. N Engl J Med. 384:2202–2211. 2021.PubMed/NCBI View Article : Google Scholar
|
|
65
|
Bayas A, Menacher M, Christ M, Behrens L, Rank A and Naumann M: Bilateral superior ophthalmic vein thrombosis, ischaemic stroke, and immune thrombocytopenia after ChAdOx1 nCoV-19 vaccination. Lancet. 397(e11)2021.PubMed/NCBI View Article : Google Scholar
|
|
66
|
Wolf ME, Luz B, Niehaus L, Bhogal P, Bäzner H and Henkes H: Thrombocytopenia and intracranial Venous Sinus thrombosis after ‘COVID-19 vaccine AstraZeneca’ exposure. J Clin Med. 10(1599)2021.PubMed/NCBI View Article : Google Scholar
|
|
67
|
Bjørnstad-Tuveng TH, Rudjord A and Anker P: Fatal cerebral haemorrhage after COVID-19 vaccine. Tidsskr Nor Laegeforen. 141:2021.PubMed/NCBI View Article : Google Scholar : (In English, Norwegian).
|
|
68
|
Pottegård A, Lund LC, Karlstad Ø, Dahl J, Andersen M, Hallas J, Lidegaard Ø, Tapia G, Gulseth HL, Ruiz PL, et al: Arterial events, venous thromboembolism, thrombocytopenia, and bleeding after vaccination with Oxford-AstraZeneca ChAdOx1-S in Denmark and Norway: Population based cohort study. BMJ. 373(n1114)2021.PubMed/NCBI View Article : Google Scholar
|
|
69
|
European Medicined Agency (EMA): AstraZeneca's COVID-19 vaccine: EMA finds possible link to very rare cases of unusual blood clots with low blood platelets. EMA, Amsterdam, 2021. https://www.ema.europa.eu/en/news/astrazenecas-covid-19-vaccine-ema-finds-possible-link-very-rare-cases-unusual-blood-clots-low-blood. Accessed April 7, 2021.
|
|
70
|
Sadoff J, Le Gars M, Shukarev G, Heerwegh D, Truyers C, de Groot AM, Stoop J, Tete S, Van Damme W, Leroux-Roels I, et al: Interim Results of a Phase 1-2a Trial of Ad26.COV2.S Covid-19 vaccine. N Engl J Med. 384:1824–1835. 2021.PubMed/NCBI View Article : Google Scholar
|
|
71
|
Sadoff J, Gray G, Vandebosch A, Cárdenas V, Shukarev G, Grinsztejn B, Goepfert PA, Truyers C, Fennema H, Spiessens B, et al: Safety and efficacy of single-dose Ad26.COV2.S vaccine against Covid-19. N Engl J Med. 384:2187–2201. 2021.PubMed/NCBI View Article : Google Scholar
|
|
72
|
Jongeneelen M, Kaszas K, Veldman D, Huizingh J, van der Vlugt R, Schouten T, Zuijdgeest D, Uil T, van Roey G, Guimera N, et al: Ad26.COV2.S elicited neutralizing activity against Delta and other SARS-CoV-2 variants of concern. bioRxiv: doi: https://doi.org/10.1101/2021.07.01.450707.
|
|
73
|
JanssenMD®: Janssen COVID-19 Vaccine - Adverse Event - Hypersensitivity and Anaphylaxis Reactions. https://www.janssenmd.com/janssen-covid19-vaccine/safety/hypersensitivity-reactions/janssen-covid19-vaccine-adverse-event-hypersensitivity-and-anaphylaxis-reactions. Last Updated July 15, 2021.
|
|
74
|
HCP Live: Janssen's COVID-19 Vaccine Shows Efficacy in Phase 3 Data. https://www.hcplive.com/view/janssen-covid-19-vaccine-efficacy-phase-3-data. Accessed February 24, 2021.
|
|
75
|
See I, Su JR, Lale A, Woo EJ, Guh AY, Shimabukuro TT, Streiff MB, Rao AK, Wheeler AP, Beavers SF, et al: US case reports of Cerebral Venous Sinus thrombosis with thrombocytopenia after Ad26.COV2.S vaccination, March 2 to April 21, 2021. JAMA. 325:2448–2456. 2021.PubMed/NCBI View Article : Google Scholar
|
|
76
|
Ophinni Y, Hasibuan AS, Widhani A, Maria S, Koesnoe S, Yunihastuti E, Karjadi TH, Rengganis I and Djauzi S: COVID-19 vaccines: Current status and implication for use in Indonesia. Acta Med Indones. 52:388–412. 2020.PubMed/NCBI
|
|
77
|
Jackson LA, Anderson EJ, Rouphael NG, Roberts PC, Makhene M, Coler RN, McCullough MP, Chappell JD, Denison MR, Stevens LJ, et al: An mRNA vaccine against SARS-CoV-2-Preliminary Report. N Engl J Med. 383:1920–1931. 2020.PubMed/NCBI View Article : Google Scholar
|
|
78
|
Mishra S: An Infectious Disease Expert Explains The Results from Moderna's Latest Vaccine Trials. The Conversation Trust (UK), London, 2020. https://theconversation.com/video-an-infectious-disease-expert-explains-the-results-from-modernas-latest-vaccine-trials-142888. Accessed July 18, 2020.
|
|
79
|
US National Library of Medicine (NIH): Dose-Confirmation Study to Evaluate the Safety Reactogenicity and Immunogenicity of mRNA-1273 COVID-19 Vaccine in Adults Aged 18 Years and Older. ClinicalTrials.gov Identifier: NCT04405076. NIH, Bethesda, MD, 2020. https://www.clinicaltrials.gov/ct2/show/NCT04405076?term=moderna&cond=covid-19&draw=2. Accessed July 6, 2020.
|
|
80
|
Baden LR, El Sahly HM, Essink B, Kotloff K, Frey S, Novak R, Diemert D, Spector SA, Rouphael N, Creech CB, et al: Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med. 384:403–416. 2021.
|
|
81
|
US National Library of Medicine (NIH): A Study to Evaluate Safety and Effectiveness of mRNA-1273 Vaccine in Healthy Children Between 6 Months of Age and Less Than 12 Years of Age. NIH, Bethesda, MD, 2021. https://www.clinicaltrials.gov/ct2/history/NCT04796896?V_1=View. Accessed March 11, 2021.
|
|
82
|
Wu K, Werner AP, Koch M, Choi A, Narayanan E, Stewart-Jones GBE, Colpitts T, Bennett H, Boyoglu-Barnum S, Shi W, et al: Serum neutralizing activity elicited by mRNA-1273 vaccine. N Engl J Med. 383:2427–2438. 2021.PubMed/NCBI View Article : Google Scholar
|
|
83
|
Planas D, Bruel T, Grzelak L, Guivel-Benhassine F, Staropoli I, Porrot F, Planchais C, Buchrieser J, Rajah MM, Bishop E, et al: Sensitivity of infectious SARS-CoV-2 B.1.1.7 and B.1.351 variants to neutralizing antibodies. Nat Med. 27:917–924. 2021.PubMed/NCBI View Article : Google Scholar
|
|
84
|
Wu K, Werner AP, Moliva JI, Koch M, Choi A, Stewart-Jones GBE, Bennett H, Boyoglu-Barnum S, Shi W, Graham BS, et al: mRNA-1273 vaccine induces neutralizing antibodies against spike mutants from global SARS-CoV-2 variants. bioRxiv: doi: https://doi.org/10.1101/2021.01.25.427948.
|
|
85
|
GOV.UK: Decision. Summary of Product Characteristics for Spikevax. https://www.gov.uk/government/publications/regulatory-approval-of-covid-19-vaccine-moderna/information-for-healthcare-professionals-on-covid-19-vaccine-moderna. Updated August 20, 2021.
|
|
86
|
Vaccines and Related Biological Products Advisory Committee Meeting Date: 17 December 2020. https://www.fda.gov/advisory-committees/advisory-committee-calendar/vaccines-and-related-biological-products-advisory-committee-december-17-2020-meeting-announcement. Accessed December 17, 2020.
|
|
87
|
Walsh EE, Frenck RW Jr, Falsey AR, Kitchin N, Absalon J, Gurtman A, Lockhart S, Neuzil K, Mulligan MJ, Bailey R, et al: Safety and immunogenicity of two RNA-based Covid-19 vaccine candidates. N Engl J Med. 383:2439–2450. 2020.PubMed/NCBI View Article : Google Scholar
|
|
88
|
Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, Perez JL, Pérez Marc G, Moreira ED, Zerbini C, et al: Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med. 383:2603–2615. 2020.PubMed/NCBI View Article : Google Scholar
|
|
89
|
Lopez Bernal J, Andrews N, Gower C, Robertson C, Stowe J, Tessier E, Simmons R, Cottrell S, Roberts R, O'Doherty M, et al: Effectiveness of the Pfizer-BioNTech and Oxford-AstraZeneca vaccines on covid-19 related symptoms, hospital admissions, and mortality in older adults in England: test negative case-control study. BMJ. 373(n1088)2021.PubMed/NCBI View Article : Google Scholar
|
|
90
|
Pritchard E, Matthews PC, Stoesser N, Eyre DW, Gethings O, Vihta KD, Jones J, House T, VanSteenHouse H, Bell I, et al: Impact of vaccination on new SARS-CoV-2 infections in the United Kingdom. Nat Med. 27:1370–1378. 2021.PubMed/NCBI View Article : Google Scholar
|
|
91
|
Hall VJ, Foulkes S, Saei A, Andrews N, Oguti B, Charlett A, Wellington E, Stowe J, Gillson N, Atti A, et al: COVID-19 vaccine coverage in health-care workers in England and effectiveness of BNT162b2 mRNA vaccine against infection (SIREN): A prospective, multicentre, cohort study. Lancet. 397:1725–1735. 2021.PubMed/NCBI View Article : Google Scholar
|
|
92
|
Pfizer: Pfizer and BioNTech Confirm High Efficacy and No Serious Safety Concerns Through Up to Six Months Following Second Dose in Updated Topline Analysis of Landmark COVID-19 Vaccine Study. Pfizer, New York, NY, 2021. https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-confirm-high-efficacy-and-no-serious. Accessed April 1, 2021.
|
|
93
|
Dejnirattisai W, Zhou D, Supasa P, Liu C, Mentzer AJ, Ginn HM, Zhao Y, Duyvesteyn HME, Tuekprakhon A, Nutalai R, et al: Antibody evasion by the P.1 strain of SARS-CoV-2. Cell. 184:2939–2954. 2021.PubMed/NCBI View Article : Google Scholar
|
|
94
|
Parry H, Bruton R, Tut G, Ali M, Stephens C, Greenwood D, Faustini S, Hughes S, Huissoon A, Meade R, et al: Immunogenicity of single vaccination with BNT162b2 or ChAdOx1 nCoV-19 at 5-6 weeks post vaccine in participants aged 80 years or older: An exploratory analysis. Lancet Healthy Longev. 2:e554–e560. 2021.PubMed/NCBI View Article : Google Scholar
|
|
95
|
Lustig Y, Zuckerman N, Nemet I, Atari N, Kliker L, Regev-Yochay G, Sapir E, Mor O, Alroy-Preis S, Mendelson E and Mandelboim M: Neutralising capacity against Delta (B.1.617.2) and other variants of concern following Comirnaty (BNT162b2, BioNTech/Pfizer) vaccination in health care workers Israel. Euro Surveill. 26(2100557)2021.PubMed/NCBI View Article : Google Scholar
|
|
96
|
Hacisuleyman E, Hale C, Saito Y, Blachere NE, Bergh M, Conlon EG, Schaefer-Babajew DJ, DaSilva J, Muecksch F, Gaebler C, et al: Vaccine breakthrough infections with SARS-CoV-2 Variants. N Engl J Med. 384:2212–2218. 2021.PubMed/NCBI View Article : Google Scholar
|
|
97
|
Geers D, Shamier MC, Bogers S, den Hartog G, Gommers L, Nieuwkoop NN, Schmitz KS, Rijsbergen LC, van Osch JAT, Dijkhuizen E, et al: SARS-CoV-2 variants of concern partially escape humoral but not T-cell responses in COVID-19 convalescent donors and vaccinees. Sci Immunol. 6(eabj1750)2021.PubMed/NCBI View Article : Google Scholar
|
|
98
|
Public Health England: Public Health England vaccine effectiveness report March 2021. https://www.gov.uk/government/publications/phe-monitoring-of-the-effectiveness-of-covid-19-vaccination. Accessed March 17, 2021.
|
|
99
|
Levine-Tiefenbrun M, Yelin I, Katz R, Herzel E, Golan Z, Schreiber L, Wolf T, Nadler V, Ben-Tov A, Kuint J, et al: Initial report of decreased SARS-CoV-2 viral load after inoculation with the BNT162b2 vaccine. Nat Med. 27:790–792. 2021.PubMed/NCBI View Article : Google Scholar
|
|
100
|
Angel Y, Spitzer A, Henig O, Saiag E, Sprecher E, Padova H and Ben-Ami R: Association between vaccination with BNT162b2 and incidence of symptomatic and asymptomatic SARS-CoV-2 infections among health care workers. JAMA. 325:2457–2465. 2021.PubMed/NCBI View Article : Google Scholar
|
|
101
|
Haas EJ, Angulo FJ, McLaughlin JM, Anis E, Singer SR, Khan F, Brooks N, Smaja M, Mircus G, Pan K, et al: Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: An observational study using national surveillance data. Lancet. 397:1819–1829. 2021.PubMed/NCBI View Article : Google Scholar
|
|
102
|
Jones NK, Rivett L, Seaman S, Samworth RJ, Warne B, Workman C, Ferris M, Wright J, Quinnell N, Shaw A, et al: Single-dose BNT162b2 vaccine protects against asymptomatic SARS-CoV-2 infection. Elife. 10(e68808)2021.PubMed/NCBI View Article : Google Scholar
|
|
103
|
GOV.UK: COVID-19 mRNA Pfizer-BioNTech vaccine analysis print. https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1020030/COVID-19_mRNA_Pfizer-_BioNTech_vaccine_analysis_print.pdf. Accessed September 17, 2021.
|
|
104
|
Chapin-Bardales J, Gee J and Myers T: Reactogenicity following receipt of mRNA-Based COVID-19 vaccines. JAMA. 325:2201–2202. 2021.PubMed/NCBI View Article : Google Scholar
|
|
105
|
Meo SA, Bukhari IA, Akram J, Meo AS and Klonoff DC: COVID-19 vaccines: Comparison of biological, pharmacological characteristics and adverse effects of Pfizer/BioNTech and Moderna vaccines. Eur Rev Med Pharmacol Sci. 25:1663–1669. 2021.PubMed/NCBI View Article : Google Scholar
|
|
106
|
Bhattacharjee S and Banerjee M: Immune Thrombocytopenia Secondary to COVID-19: A systematic review. SN Compr Clin Med: Sep 19, 2020 (Epub ahead of print).
|
|
107
|
Weyrich AS, Schwertz H, Kraiss LW and Zimmerman GA: Protein synthesis by platelets: Historical and new perspectives. J Thromb Haemost. 7:241–246. 2009.PubMed/NCBI View Article : Google Scholar
|
|
108
|
Raadsen M, Du Toit J, Langerak T, van Bussel B, van Gorp E and Goeijenbier M: Thrombocytopenia in virus Infections. J Clin Med. 10(877)2021.PubMed/NCBI View Article : Google Scholar
|
|
109
|
Welsh KJ, Baumblatt J, Chege W, Goud R and Nair N: Thrombocytopenia including immune thrombocytopenia after receipt of mRNA COVID-19 vaccines reported to the Vaccine Adverse Event Reporting System (VAERS). Vaccine. 39:3329–3332. 2021.PubMed/NCBI View Article : Google Scholar
|
|
110
|
Guimarães LE, Baker B, Perricone C and Shoenfeld Y: Vaccines, adjuvants and autoimmunity. Pharmacol Res. 100:190–209. 2015.PubMed/NCBI View Article : Google Scholar
|
|
111
|
European Medicined Agency (EMA): COVID-19 Vaccine AstraZeneca: PRAC investigating cases of thromboembolic events - vaccine's benefits currently still outweigh risks - Update. EMA, Amsterdam, 2021. https://www.ema.europa.eu/en/news/covid-19-vaccine-astrazeneca-prac-investigating-cases-thromboembolic-events-vaccines-benefits. Accessed March 11, 2021.
|
|
112
|
Shimabukuro TT, Kim SY, Myers TR, Moro PL, Oduyebo T, Panagiotakopoulos L, Marquez PL, Olson CK, Liu R, Chang KT, et al: Preliminary findings of mRNA COVID-19 vaccine safety in pregnant persons. N Engl J Med. 384:2273–2282. 2021.PubMed/NCBI View Article : Google Scholar
|
|
113
|
García-Montero C, Fraile-Martínez O, Bravo C, Torres-Carranza D, Sanchez-Trujillo L, Gómez-Lahoz AM, Guijarro LG, García-Honduvilla N, Asúnsolo A, Bujan J, et al: An updated review of SARS-CoV-2 vaccines and the importance of effective vaccination programs in pandemic times. Vaccines (Basel). 9(433)2021.PubMed/NCBI View Article : Google Scholar
|
|
114
|
GOV.UK: Vaccinations in United Kingdom. https://coronavirus.data.gov.uk/details/vaccinations. Last Updated September 26, 2021.
|
|
115
|
Office of National Statistics (ONS): Coronavirus (COVID-19) latest insights. ONS, London, 2021. https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/articles/coronaviruscovid19/latestinsights.
|
|
116
|
Wei J, Stoesser N, Matthews PC, Ayoubkhani D, Studley R, Bell I, Bell JI, Newton JN, Farrar J, Diamond I, et al: Antibody responses to SARS-CoV-2 vaccines in 45,965 adults from the general population of the United Kingdom. Nat Microbiol. 6:1140–1149. 2021.PubMed/NCBI View Article : Google Scholar
|
|
117
|
Dagan N, Barda N, Kepten E, Miron O, Perchik S, Katz MA, Hernán MA, Lipsitch M, Reis B and Balicer RD: BNT162b2 mRNA Covid-19 vaccine in a Nationwide mass vaccination setting. N Engl J Med. 384:1412–1423. 2021.
|
|
118
|
Shrotri M, Navaratnam AMD, Nguyen V, Byrne T, Geismar C, Fragaszy E, Beale S, Fong WLE, Patel P, Kovar J, et al: Spike-antibody waning after second dose of BNT162b2 or ChAdOx1. Lancet. 398:385–387. 2021.PubMed/NCBI View Article : Google Scholar
|
|
119
|
Rossman H, Shilo S, Meir T, Gorfine M, Shalit U and Segal E: COVID-19 dynamics after a national immunization program in Israel. Nat Med. 27:1055–1061. 2021.PubMed/NCBI View Article : Google Scholar
|
|
120
|
European Centre for Disease Prevention and Control (ECDC): Rapid risk assessment: Assessing SARS-CoV-2 circulation, variants of concern, non-pharmaceutical interventions and vaccine rollout the EU/EEA 15th update. ECDC, Stockholm, 2021. https://www.ecdc.europa.eu/en/publications-data/rapid-risk-assessment-sars-cov-2-circulation-variants-concern. Accessed June 10, 2021.
|
|
121
|
McNamara D: Delta Variant Key to Breakthrough Infections in Vaccinated Israelis. Medscape, 2021. https://www.medscape.com/viewarticle/954357. Accessed July 7, 2021.
|
|
122
|
GOV.UK: Investigation of SARS-CoV-2 variants of concern: technical briefings. https://www.gov.uk/government/publications/investigation-of-novel-sars-cov-2-variant-variant-of-concern-20201201. Accessed December 21, 2020.
|
|
123
|
Lopez Bernal J, Andrews N, Gower C, Gallagher E, Simmons R, Thelwall S, Stowe J, Tessier E, Groves N, Dabrera G, et al: Effectiveness of Covid-19 vaccines against the B.1.617.2 (Delta) Variant. N Engl J Med. 385:585–594. 2021.PubMed/NCBI View Article : Google Scholar
|
|
124
|
Barouch DH, Stephenson KE, Sadoff J, Yu J, Chang A, Gebre M, McMahan K, Liu J, Chandrashekar A, Patel S, et al: Durable humoral and cellular immune responses 8 months after Ad26.COV2.S vaccination. N Engl J Med. 385:951–953. 2021.PubMed/NCBI View Article : Google Scholar
|
|
125
|
Sheikh A, McMenamin J, Taylor B and Robertson C: Public Health Scotland and the EAVE II Collaborators. SARS-CoV-2 Delta VOC in Scotland: Demographics, risk of hospital admission, and vaccine effectiveness. Lancet. 397:2461–2462. 2021.PubMed/NCBI View Article : Google Scholar
|
|
126
|
Choi A, Koch M, Wu K, Dixon G, Oestreicher J, Legault H, Stewart-Jones GBE, Colpitts T, Pajón R, Bennett H, et al: Serum neutralizing activity of mRNA-1273 against SARS-CoV-2 Variants. J Virol JVI0131321, 2021 (Epub ahead of print).
|
|
127
|
Nasreen S, Chung H, K. He S, Brown A, Gubbay JB, Buchan SA, Fell DB, Austin PC, Schwartz KL, M. Sndaram ME, et al: Effectiveness of COVID-19 vaccines against variants of concern, Canada. medRxiv: doi: https://doi.org/10.1101/2021.06.28.21259420.
|
|
128
|
Tada T, Zhou H, Samanovic MI, Dcosta BM, Cornelius A, Mulligan MJ and Landau NR: Comparison of neutralizing antibody Titers Elicited by mRNA and Adenoviral vector vaccine against SARS-CoV-2 Variants. bioRxiv: doi: 10.1101/2021.07.19.452771.
|
|
129
|
Nanduri S, Pilishvili T, Derado G, Soe MM, Dollard P, Wu H, Li Q, Bagchi S, Dubendris H, Link-Gelles R, et al: Effectiveness of Pfizer-BioNTech and Moderna vaccines in preventing SARS-CoV-2 infection among nursing home residents before and during widespread circulation of the SARS-CoV-2 B.1.617.2 (Delta) Variant-National Healthcare Safety Network, March 1-August 1, 2021. MMWR Morb Mortal Wkly Rep. 70:1163–1166. 2021.PubMed/NCBI View Article : Google Scholar
|
|
130
|
Centers for Disease Control and Prevention (CDC): Interim Clinical Considerations for Use of COVID-19 Vaccines Currently Approved or Authorized in the United States. CDC, Atlanta, GA, 2021. https://www.cdc.gov/vaccines/covid-19/clinical-considerations/covid-19-vaccines-us.html. Last Updated September 15, 2021.
|
|
131
|
Centers for Disease Control and Prevention (CDC): Understanding mRNA COVID-19 Vaccines. CDC, Atlanta, GA, 2021. https://www.cdc.gov/coronavirus/2019-ncov/vaccines/different-vaccines/mrna.html. Accessed March 4, 2021.
|
|
132
|
Zhang C, Maruggi G, Shan H and Li J: Advances in mRNA vaccines for infectious diseases. Front Immunol. 10(594)2019.PubMed/NCBI View Article : Google Scholar
|
|
133
|
Jackson NAC, Kester KE, Casimiro D, Gurunathan S and DeRosa F: The promise of mRNA vaccines: A biotech and industrial perspective. NPJ Vaccines. 5(11)2020.PubMed/NCBI View Article : Google Scholar
|
|
134
|
Zhang NN, Li XF, Deng YQ, Zhao H, Huang YJ, Yang G, Huang WJ, Gao P, Zhou C, Zhang RR, et al: A Thermostable mRNA vaccine against COVID-19. Cell. 182:1271–1283.e16. 2020.PubMed/NCBI View Article : Google Scholar
|
|
135
|
Gray R: Q&A: How Covid-19 hijacks human cells. European Commission, Luxembourg, 2020. https://ec.europa.eu/research-and-innovation/en/horizon-magazine/qa-how-covid-19-hijacks-human-cells. Accessed December 15, 2020.
|
|
136
|
Lindsay KE, Bhosle SM, Zurla C, Beyersdorf J, Rogers KA, Vanover D, Xiao P, Araínga M, Shirreff LM, Pitard B, et al: Visualization of early events in mRNA vaccine delivery in non-human primates via PET-CT and near-infrared imaging. Nat Biomed Eng. 3:371–380. 2019.PubMed/NCBI View Article : Google Scholar
|
|
137
|
Desigaux L, Sainlos M, Lambert O, Chevre R, Letrou-Bonneval E, Vigneron JP, Lehn P, Lehn JM and Pitard B: Self-assembled lamellar complexes of siRNA with lipidic aminoglycoside derivatives promote efficient siRNA delivery and interference. Proc Natl Acad Sci USA. 104:16534–16539. 2007.PubMed/NCBI View Article : Google Scholar
|
|
138
|
Frey SE, Wald A, Edupuganti S, Jackson LA, Stapleton JT, El Sahly H, El-Kamary SS, Edwards K, Keyserling H, Winokur P, et al: Comparison of lyophilized versus liquid modified vaccinia Ankara (MVA) formulations and subcutaneous versus intradermal routes of administration in healthy vaccinia-naïve subjects. Vaccine. 33:5225–5234. 2015.PubMed/NCBI View Article : Google Scholar
|
|
139
|
Habrant D, Peuziat P, Colombani T, Dallet L, Gehin J, Goudeau E, Evrard B, Lambert O, Haudebourg T and Pitard B: Design of ionizable lipids to overcome the limiting step of endosomal escape: Application in the intracellular delivery of mRNA, DNA, and siRNA. J Med Chem. 59:3046–3062. 2016.PubMed/NCBI View Article : Google Scholar
|
|
140
|
Caballero ML, Krantz MS, Quirce S, Phillips EJ and Stone CA Jr: Hidden dangers: Recognizing excipients as potential causes of drug and vaccine hypersensitivity reactions. J Allergy Clin Immunol Pract. 9:2968–2982. 2021.PubMed/NCBI View Article : Google Scholar
|
|
141
|
Banerji A, Wickner PG, Saff R, Stone CA Jr, Robinson LB, Long AA, Wolfson AR, Williams P, Khan DA, Phillips E and Blumenthal KG: mRNA vaccines to prevent COVID-19 disease and reported allergic reactions: Current evidence and suggested approach. J Allergy Clin Immunol Pract. 9:1423–1437. 2021.PubMed/NCBI View Article : Google Scholar
|
|
142
|
Cabanillas B, Akdis C and Novak N: Allergic reactions to the first COVID-19 vaccine: A potential role of Polyethylene glycol? Allergy. 76:1617–1618. 2021.PubMed/NCBI View Article : Google Scholar
|
|
143
|
Garvey LH and Nasser S: Anaphylaxis to the first COVID-19 vaccine: Is polyethylene glycol (PEG) the culprit? Br J Anaesth. 126:e106–e108. 2021.PubMed/NCBI View Article : Google Scholar
|
|
144
|
Yu RJ, Krantz MS, Phillips EJ and Stone CA Jr: Emerging causes of drug-induced anaphylaxis: A review of anaphylaxis-associated reports in the FDA Adverse Event Reporting System (FAERS). J Allergy Clin Immunol Pract. 9:819–829.e2. 2021.PubMed/NCBI View Article : Google Scholar
|
|
145
|
Chung CH, Mirakhur B, Chan E, Le QT, Berlin J, Morse M, Murphy BA, Satinover SM, Hosen J, Mauro D, et al: Cetuximab-induced anaphylaxis and IgE specific for galactose-alpha-1,3-galactose. N Engl J Med. 358:1109–1117. 2008.PubMed/NCBI View Article : Google Scholar
|
|
146
|
Wenande E and Garvey LH: Immediate-type hypersensitivity to polyethylene glycols: A review. Clin Exp Allergy. 46:907–922. 2016.PubMed/NCBI View Article : Google Scholar
|
|
147
|
Centers for Disease Control and Prevention (CDC): When You've Been Fully Vaccinated. How to Protect Yourself and Others. CDC, Atlanta, GA, 2021. https://www.cdc.gov/coronavirus/2019-ncov/vaccines/fully-vaccinated.html. Updated September 16, 2021.
|
|
148
|
Mazagatos C, Monge S, Olmedo C, Vega L, Gallego P, Martín-Merino E, Sierra MJ, Limia A and Larrauri A: Working Group for the surveillance and control of COVID-19 in Spain; Working group for the surveillance and control of COVID-19 in Spain. Effectiveness of mRNA COVID-19 vaccines in preventing SARS-CoV-2 infections and COVID-19 hospitalisations and deaths in elderly long-term care facility residents, Spain, weeks 53 2020 to 13 2021. Euro Surveill. 26(2100452)2021.PubMed/NCBI View Article : Google Scholar
|
|
149
|
Centers for Disease Control and Prevention (CDC): Coronavirus Disease 2019 (COVID-19), People who are at higher risk for severe illness. CDC, Atlanta, GA, 2021. https://www.cdc.gov/coronavirus/2019-ncov/need-extra-precautions/groups-at-higher-risk.html. Updated August 20, 2021].
|
|
150
|
Dan JM, Mateus J, Kato Y, Hastie KM, Yu ED, Faliti CE, Grifoni A, Ramirez SI, Haupt S, Frazier A, et al: Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection. Science. 371(eabf4063)2021.PubMed/NCBI View Article : Google Scholar
|
|
151
|
Centers for Disease Control and Prevention (CDC): When You've Been Fully Vaccinated. How to Protect Yourself and Others. CDC, Atlanta, GA, 2021. https://www.cdc.gov/coronavirus/2019-ncov/vaccines/fully-vaccinated-guidance.html. Updated September 16, 2021.
|
|
152
|
Foy BH, Wahl B, Mehta K, Shet A, Menon GI and Britto C: Comparing COVID-19 vaccine allocation strategies in India: A mathematical modelling study. Int J Infect Dis. 103:431–438. 2021.PubMed/NCBI View Article : Google Scholar
|
|
153
|
Gokbulut N, Kuymakamzade B, Sanlidag T and Hincal E: Mathematical modelling of Covid-19 with the effect of vaccine. AIP Conference Proceedings. 2325(020065)2021.
|
|
154
|
Jentsch PC, Anand M and Bauch CT: Prioritising COVID-19 vaccination in changing social and epidemiological landscapes: A mathematical modelling study. Lancet Infect Dis. 21:1097–1106. 2021.PubMed/NCBI View Article : Google Scholar
|
|
155
|
Martinez-Rodriguez D, Gonzalez-Parra G and Villanueva RJ: Analysis of key factors of a SARS-CoV-2 vaccination program: A mathematical modeling approach. Epidemiologia. 2:140–161. 2021.
|
|
156
|
Webb G: A COVID-19 epidemic model predicting the effectiveness of vaccination in the US. Infect Dis Rep. 13:654–667. 2021.PubMed/NCBI View Article : Google Scholar
|
|
157
|
Chaturvedi D and Chakravarty U: Predictive analysis of COVID-19 eradication with vaccination in India, Brazil, and USA. Infect Genet Evol. 92(104834)2021.PubMed/NCBI View Article : Google Scholar
|
|
158
|
McDonnell A, Van Exan R, Lloyd S, Subramanian L, Chalkidou K, La Porta A, Li J, Maiza E, Reader D, Rosenberg J, et al: COVID-19 Vaccine predictions: Using mathematical modelling and expert opinions to estimate timelines and probabilities of success of COVID-19 vaccines. Center for Global Development, Washington, DC, 2020. https://www.cgdev.org/publication/covid-19-vaccine-predictions. Accessed October 1, 2020.
|
